Ultomiris (ravulizumab-cwvz) was associated with sustained disease control in people with neuromyelitis optica spectrum disorder (NMOSD), regardless of whether they had been previously treated off-label with rituximab. That’s according to a new analysis of data from the Phase 3 CHAMPION-NMOSD clinical trial (NCT04201262), whose results supported…
Discussion
At 44, I’ve reached the age where life starts handing out plot twists no one asked for. Parents get sick. Friends, the same ones I once stayed out too late with, now text me about big health issues. And every so often, someone disappears entirely, leaving a silence that feels…
Most documented safety issues reported during Enspryng (satralizumab-mwge) treatment for neuromyelitis optica spectrum disorder (NMOSD) in a real-world database have been consistent with the therapy’s reported safety profile in clinical trials, a study showed. Simultaneous use of corticosteroids, a common anti-inflammatory treatment in NMOSD, was associated with higher…
NMOSD is a progressive autoimmune disease where the immune system mistakenly attacks nerve cells, affecting the nervous system. Learn more about the disease here.
Scientists do not know the exact underlying cause of NMOSD. Self-reactive antibodies that target AQP4 are known to play a major role. Learn more about what causes the disease here.
When the disease affects the optic nerve (optic neuritis), it can result in pain inside the eye and possibly blurry vision or vision loss. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
